Literature DB >> 15596827

Role for tumor necrosis factor alpha in murine cytomegalovirus transcriptional reactivation in latently infected lungs.

Christian O Simon1, Christof K Seckert, Doris Dreis, Matthias J Reddehase, Natascha K A Grzimek.   

Abstract

Interstitial pneumonia is a major clinical manifestation of primary or recurrent cytomegalovirus (CMV) infection in immunocompromised recipients of a bone marrow transplant. In a murine model, lungs were identified as a prominent site of CMV latency and recurrence. Pulmonary latency of murine CMV is characterized by high viral genome burden and a low incidence of variegated immediate-early (IE) gene expression, reflecting a sporadic activity of the major IE promoters (MIEPs) and enhancer. The enhancer-flanking promoters MIEP1/3 and MIEP2 are switched on and off during latency in a ratio of approximately 2:1. MIEP1/3 latency-associated activity generates the IE1 transcript of the ie1/3 transcription unit but not the alternative splicing product IE3 that encodes the essential transactivator of early gene expression. Splicing thus appeared to be an important checkpoint for maintenance of latency. In accordance with previous work of others, we show here that signaling by the proinflammatory cytokine tumor necrosis factor alpha (TNF-alpha) activates IE1/3 transcription in vivo. As an addition to current knowledge, Poisson distribution analysis revealed an increased incidence of IE1/3 transcriptional events as well as a higher amount of transcripts per event. Notably, TNF-alpha promoted the splicing to IE3 transcripts, but transcription did not proceed to the M55/gB early gene. Moreover, the activated transcriptional state induced by TNF-alpha did not predispose latently infected mice to a higher incidence of virus recurrence after hematoablative treatment. In conclusion, TNF-alpha is an important inductor of IE gene transcriptional reactivation, whereas early genes downstream in the viral replicative cycle appear to be the rate-limiting checkpoint(s) for virus recurrence.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15596827      PMCID: PMC538715          DOI: 10.1128/JVI.79.1.326-340.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  A long and complex enhancer activates transcription of the gene coding for the highly abundant immediate early mRNA in murine cytomegalovirus.

Authors:  K Dorsch-Häsler; G M Keil; F Weber; M Jasin; W Schaffner; U H Koszinowski
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

2.  Detection of murine cytomegalovirus immediate early 1 transcripts in the spleens of latently infected mice.

Authors:  S C Henry; J D Hamilton
Journal:  J Infect Dis       Date:  1993-04       Impact factor: 5.226

3.  Structure of the mouse gene encoding parathyroid hormone-related peptide.

Authors:  M Mangin; K Ikeda; A E Broadus
Journal:  Gene       Date:  1990-11-15       Impact factor: 3.688

4.  Identification and characterization of the human cytomegalovirus immediate-early region 2 gene that stimulates gene expression from an inducible promoter.

Authors:  T W Hermiston; C L Malone; P R Witte; M F Stinski
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

5.  Lungs are a major organ site of cytomegalovirus latency and recurrence.

Authors:  M Balthesen; M Messerle; M J Reddehase
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

6.  Selective species specificity of tumor necrosis factor for toxicity in the mouse.

Authors:  P Brouckaert; C Libert; B Everaerdt; W Fiers
Journal:  Lymphokine Cytokine Res       Date:  1992-08

7.  Structural organization, expression, and functional characterization of the murine cytomegalovirus immediate-early gene 3.

Authors:  M Messerle; B Bühler; G M Keil; U H Koszinowski
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

8.  Tumour necrosis factor alpha stimulates the activity of the human cytomegalovirus major immediate early enhancer/promoter in immature monocytic cells.

Authors:  J Stein; H D Volk; C Liebenthal; D H Krüger; S Prösch
Journal:  J Gen Virol       Date:  1993-11       Impact factor: 3.891

9.  The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease.

Authors:  M J Reddehase; M Balthesen; M Rapp; S Jonjić; I Pavić; U H Koszinowski
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

10.  A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes.

Authors:  J Gubbay; J Collignon; P Koopman; B Capel; A Economou; A Münsterberg; N Vivian; P Goodfellow; R Lovell-Badge
Journal:  Nature       Date:  1990-07-19       Impact factor: 49.962

View more
  55 in total

1.  Enhancerless cytomegalovirus is capable of establishing a low-level maintenance infection in severely immunodeficient host tissues but fails in exponential growth.

Authors:  Jürgen Podlech; Rares Pintea; Kai A Kropp; Annette Fink; Niels A W Lemmermann; Katja C Erlach; Elena Isern; Ana Angulo; Peter Ghazal; Matthias J Reddehase
Journal:  J Virol       Date:  2010-04-07       Impact factor: 5.103

2.  Lipopolysaccharide, tumor necrosis factor alpha, or interleukin-1beta triggers reactivation of latent cytomegalovirus in immunocompetent mice.

Authors:  Charles H Cook; Joanne Trgovcich; Peter D Zimmerman; Yingxue Zhang; Daniel D Sedmak
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 3.  Role of the cytomegalovirus major immediate early enhancer in acute infection and reactivation from latency.

Authors:  Mark F Stinski; Hiroki Isomura
Journal:  Med Microbiol Immunol       Date:  2007-12-19       Impact factor: 3.402

4.  Murine cytomegalovirus dissemination but not reactivation in donor-positive/recipient-negative allogeneic kidney transplantation can be effectively prevented by transplant immune tolerance.

Authors:  Anil Dangi; Shuangjin Yu; Frances T Lee; Melanie Burnette; Jiao-Jing Wang; Yashpal S Kanwar; Zheng J Zhang; Michael Abecassis; Edward B Thorp; Xunrong Luo
Journal:  Kidney Int       Date:  2020-02-21       Impact factor: 10.612

5.  The immune evasion paradox: immunoevasins of murine cytomegalovirus enhance priming of CD8 T cells by preventing negative feedback regulation.

Authors:  Verena Böhm; Christian O Simon; Jürgen Podlech; Christof K Seckert; Dorothea Gendig; Petra Deegen; Dorothea Gillert-Marien; Niels A W Lemmermann; Rafaela Holtappels; Matthias J Reddehase
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

Review 6.  Impact of cytomegalovirus load on host response to sepsis.

Authors:  Thomas Marandu; Michael Dombek; Charles H Cook
Journal:  Med Microbiol Immunol       Date:  2019-04-11       Impact factor: 3.402

Review 7.  Viral latency drives 'memory inflation': a unifying hypothesis linking two hallmarks of cytomegalovirus infection.

Authors:  Christof K Seckert; Marion Griessl; Julia K Büttner; Sabine Scheller; Christian O Simon; Kai A Kropp; Angélique Renzaho; Birgit Kühnapfel; Natascha K A Grzimek; Matthias J Reddehase
Journal:  Med Microbiol Immunol       Date:  2012-09-19       Impact factor: 3.402

8.  Clinical significance of cytomegalovirus infection in patients with inflammatory bowel disease.

Authors:  Elena Garrido; Elisa Carrera; Rebeca Manzano; Antonio Lopez-Sanroman
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

9.  Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells.

Authors:  Christopher M Snyder; Kathy S Cho; Elizabeth L Bonnett; Serani van Dommelen; Geoffrey R Shellam; Ann B Hill
Journal:  Immunity       Date:  2008-10-17       Impact factor: 31.745

10.  The mouse cytomegalovirus immediate-early 1 gene is not required for establishment of latency or for reactivation in the lungs.

Authors:  Andreas Busche; Anja Marquardt; Andre Bleich; Peter Ghazal; Ana Angulo; Martin Messerle
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.